Tecfidera
Drug
Alkermes, Inc.
Total Payments
$2.2M
Transactions
1,060
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.2M | 1,060 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.2M | 1,060 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 | Alkermes, Inc. | $2.2M | 0 |
Top Doctors Receiving Payments for Tecfidera
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Basalt, CO | $2.2M | 1,060 |
Ad
Manufacturing Companies
- Alkermes, Inc. $2.2M
Product Information
- Type Drug
- Total Payments $2.2M
- Total Doctors 0
- Transactions 1,060
About Tecfidera
Tecfidera is a drug associated with $2.2M in payments to 0 healthcare providers, recorded across 1,060 transactions in the CMS Open Payments database. The primary manufacturer is Alkermes, Inc..
Payment data is available from 2019 to 2019. In 2019, $2.2M was paid across 1,060 transactions to 0 doctors.
The most common payment nature for Tecfidera is "Unspecified" ($2.2M, 100.0% of total).
Tecfidera is associated with 1 research study, including "A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700" ($2.2M).